Abstract
The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively. A total of 1120 patients who underwent complete resection were enrolled in this study. Multivariate analysis revealed that COP-LMR is an independent prognostic factor for disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001). Kaplan-Meier analysis and the log-rank test revealed that COP-LMR stratified the patients into 3 independent groups (P<0.001). In conclusion, COP-LMR is a potential prognostic biomarker in patients undergoing surgery for NSCLC.
Highlights
Lung cancer is the leading cause of cancer-related mortality worldwide [1]
As dynamic reservoirs of various factors, platelets secrete a number of cytokines and growth factors from granules and lysosomes, which affect migration and proliferation, epithelial to mesenchymal transition, and angiogenic activity [12]
Platelets are a source of plateletderived growth factor, which contributes to tumor cell proliferation and angiogenesis [13]
Summary
Lung cancer is the leading cause of cancer-related mortality worldwide [1]. Radical surgery is the primary treatment strategy for lung cancer. Despite advances in lung cancer surgery, the 5-year survival rate of patients with lung cancer is still unsatisfactory. The median survival period for lung cancer in China is only 22.7 months [2]. There has been no ideal method to predict the survival of lung cancer patients. It is urgent and essential to identify a reliable prognostic factor for lung cancer patients who underwent surgery. It would enable good risk stratification by clinicians and individualized management of lung cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
